VaramirStart free · no cardSign in
IBRX as of Oct 31 · 18:04 ET
IBRXNasdaqBiological Products, (No Diagnostic Substances)

ImmunityBio, Inc. · Brief

Next report

3 days

Nov 3 · after closeest.Q3 FY26
Earnings

Expected move

Inputs

Implied vs realized

8 reportsHistory
3 of 8≥ implied
avg implied
±19.2%
avg realized
±8.7%
Jul 25 '25±19.3%▼−4.98%×0.26
Aug 5 '25±23.1%0.00%×0.00
Nov 4 '25±44.7%▲+3.37%×0.08
Jan 15 '26±15.3%▲+30.79%×2.01
Feb 23 '26±29.3%▲+12.99%×0.44
Q1 FY26±5.5%▲+7.16%×1.30
May 7 '26±6.7%▼−7.40%×1.11
Q2 FY26±10.2%▼−2.80%×0.28
quarterimplied−45%0+45%realized×
Q2 FY26±10.2%▼−2.80%×0.28
May '26±6.7%▼−7.40%×1.11
Q1 FY26±5.5%▲+7.16%×1.30
Feb '26±29.3%▲+12.99%×0.44
Jan '26±15.3%▲+30.79%×2.01
Nov '25±44.7%▲+3.37%×0.08
2 older reports
Aug '25±23.1%0.00%×0.00
Jul '25±19.3%▼−4.98%×0.26
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 3 report · est.

Bull2 of 4

4tracked funds holding IBRXN-PORT · Aug 31 '26
1.02%of State Street SPDR S&P Biotech ETF's assets, the largest tracked-fund weightN-PORT · Jun 30 '26

Bear2 of 3

5 of 8recent reports where the move came in under the options implied rangeEarnings history
8 of 24some of the largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26
AI captions · Sep 28 '26once per report · top 2 per case

Linked exposure

IBRX report session

No linked exposure.

Latest changes

30 daysAll changes
Oct 20impliedImplied move: ±20.2% into Nov 3 earnings (Oct 20 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.